EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma

Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Behzad Baradaran

EXCLI Journal · 13.03.2024 · 23 · 384-400

DOI: 10.17179/excli2023-6404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 13.03.2024. Verfasst von Mahdi Abdoli Shadbad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiform (GBM) is a commonly diagnosed brain neoplasm with a poor prognosis. Accumulating evidence has highlighted the significance of microRNA (miR) dysregulation in tumor development and progression. This study investigated the effect of hsa-miR-34a-5p and its combination with temozolomide on GBM, the related molecular mechanisms, and the signaling pathway using in-silico and in-vitro approaches. The in-silico tumor bulk and single-cell RNA sequencing analyses were done on TCGA-GTEx, CGGA, GSE13276, GSE90603, and GSE182109 datasets. After selecting the A172 cell line, hsa-miR-34a-5p mimics were transfected, and the cell viability, migration, cell cycle, clonogenicity, and apoptosis of studied groups were studied using MTT, scratch, flow cytometry, colony formation, and Annexin V/PI assays. The mRNA expression of CASP9, CASP3, CASP8, MMP2, CD44, CDK6, CDK4, CCND1, RAF1, MAP2K1, MET, SRC, and CD274 was studied using qRT-PCR method. hsa-miR-34a-5p downregulated RAF1 expression, as the signaling factor of the MAPK pathway. The combined treatment significantly downregulated the expression of MET, SRC, and MAP2K1, leading to the inhibition of the MET/MAPK pathway compared to temozolomide. Besides exerting anti-tumoral effects on the cell viability, migration, cell cycle, apoptosis, and clonogenicity of A172 cells, its combination with temozolomide enhanced temozolomide anti-tumoral effect. Compared to temozolomide, the combined treatment significantly decreased CDK4, CDK6, CCND1, and MMP2 expression. hsa-miR-34a-5p targets RAF1, as the signaling factor of the MAPK pathway, and potentiates the temozolomide anti-tumoral effect on A172 cells.

Schlagwörter

Stichwörter der Autor:innen

MAPK pathwayglioblastomahsa-miR-34a-5psingle-cell RNA sequencingtemozolomide

Autor:innen und Institutionen

  • Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Zitieren

APA

Abdoli Shadbad, M., Baghbanzadeh, A., & Baradaran, B. (2024). hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma. EXCLI Journal, 23, 384-400. https://doi.org/10.17179/excli2023-6404

Vancouver

Abdoli Shadbad M, Baghbanzadeh A, Baradaran B. hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma. EXCLI Journal. 2024;23:384-400. doi:10.17179/excli2023-6404

BibTeX
@article{AbdoliShadbad2024,
  author = {Abdoli Shadbad, Mahdi and Baghbanzadeh, Amir and Baradaran, Behzad},
  title = {hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma},
  journal = {EXCLI Journal},
  year = {2024},
  volume = {23},
  pages = {384--400},
  doi = {10.17179/excli2023-6404}
}
Kostenlos starten →